Patterns of Adherence to Raltegravir-Based Regimens and the Risk of Virological Failure Among HIV-Infected Patients: The RALTECAPS Cohort Study

被引：21

作者：

Gras, Guillaume ^{[3
]}

Schneider, Marie-Paule ^{[4
]}

Cavassini, Matthias ^{[5
]}

Lucht, Frederic ^{[6
]}

Loilier, Magalie ^{[7
]}

Verdon, Renaud ^{[2
]}

Bernard, Louis ^{[3
]}

Parienti, Jean-Jacques ^{[1
,2
]}

机构：

[1] CHU Caen, Dept Biostat & Clin Res, F-14000 Caen, France

[2] CHU Caen, Infect Dis Serv, F-14000 Caen, France

[3] CHU Tours, Dept Infect Dis, Tours, France

[4] Univ Lausanne, Dept Ambulatory Care & Community Med, Lausanne, Switzerland

[5] CHU Vaudois, Infect Dis Serv, CH-1011 Lausanne, Switzerland

[6] Ctr Hosp Univ, Dept Infect Dis, St Etienne, France

[7] CHU Caen, Dept Pharmacol, F-14000 Caen, France

来源：

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2012年 / 61卷 / 03期

关键词：

adherence; integrase inhibitor; virological failure; antiretroviral therapy; ACTIVE ANTIRETROVIRAL THERAPY; PROTEASE INHIBITOR THERAPY; TREATMENT-NAIVE; VIRAL LOAD; RESISTANCE; SUPPRESSION; TRIAL; RNA; MUTATIONS; DURATION;

D O I：

10.1097/QAI.0b013e31826cc592

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Adherence patterns and their influence on virologic outcome are well characterized for protease inhibitor (PI)- and non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens. We aimed to determine how patterns of adherence to raltegravir influence the risk of virological failure. We conducted a prospective multicenter cohort following 81 HIV-infected antiretroviral-naive or experienced subjects receiving or starting twice-a-day raltegravir-based antiretroviral therapy. Their adherence patterns were monitored using the Medication Events Monitoring System. During follow-up (188 days, +/- 77), 12 (15%) of 81 subjects experienced virological failure. Longer treatment interruption [adjusted odds ratio per 24-hour increase: 2.4; 95% confidence interval: 1.2 to 6.9; P < 0.02] and average adherence (odds ratio per 5% increase: 0.68; 95% confidence interval: 0.46 to 1.00, P < 0.05) were both independently associated with virological failure controlling for prior duration of viral suppression. Timely interdose intervals and high levels of adherence to raltegravir are both necessary to control HIV replication.

引用

页码：265 / 269

页数：5

共 34 条

[1] Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research [J].